Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alternative immunomodulators.

Alastair Forbes1

  • 1St. Mark's Hospital and Academic Institute, Harrow, UK. alastair.forbes@ic.ac.uk

European Journal of Gastroenterology & Hepatology
|March 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential time-sensitive biomarkers for the detection of acute mesenteric ischaemia: a systematic review of animal data.

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals·2026
Same author

Alterations of vitamin D metabolism and requirements in clinical conditions with impaired gastro-intestinal and renal function and in critical illness.

The Journal of steroid biochemistry and molecular biology·2025
Same author

One-year survival and quality of life after acute mesenteric ischemia: Follow-up of the AMESI study.

The journal of trauma and acute care surgery·2025
Same author

Priority setting for nutrition research in individuals with spinal cord injury: A protocol for Delphi study among health professionals.

PloS one·2025
Same author

Comparison between endovascular and surgical treatment of acute arterial occlusive mesenteric ischemia.

World journal of emergency surgery : WJES·2025
Same author

Radiological diagnosis of acute mesenteric ischemia in adult patients: a systematic review and meta-analysis.

Scientific reports·2025
Same journal

Comment on 'Associations between 12 insulin resistance surrogates with metabolic dysfunction-associated steatotic liver disease risk and all-cause mortality: data from the National Health and Nutrition Examination Survey III (1988-1994)'.

European journal of gastroenterology & hepatology·2026
Same journal

Alarm symptoms at diagnosis of coeliac disease and long-term outcomes.

European journal of gastroenterology & hepatology·2026
Same journal

Artificial intelligence-integrated nanotherapeutics for rare Peutz-Jeghers syndrome hamartoma-induced obstructions: latest clearance strategies.

European journal of gastroenterology & hepatology·2026
Same journal

'Presence of alarm symptoms at coeliac disease diagnosis is not associated with poorer long-term treatment outcomes' [Letter].

European journal of gastroenterology & hepatology·2026
Same journal

Atrial fibrillation in patients with alcohol-associated hepatitis leads to increased mortality.

European journal of gastroenterology & hepatology·2026
Same journal

Association between albumin-bilirubin score, model for end-stage liver disease score, platelet-albumin-bilirubin score, and acute-on-chronic liver failure complications: a cross-sectional study in a Chinese population.

European journal of gastroenterology & hepatology·2026
See all related articles

Novel biological agents offer promising new treatments for inflammatory bowel disease (IBD). While some newer immunosuppressants and eicosanoid modulators show limited benefit, biologics like Natalizumab and interleukin-10 hold significant potential for IBD management.

Area of Science:

  • Immunology
  • Gastroenterology
  • Pharmacology

Background:

  • Inflammatory bowel disease (IBD) management requires effective immunomodulatory agents.
  • Established treatments have limitations, necessitating exploration of novel therapeutic strategies.

Purpose of the Study:

  • To review the potential of various immunomodulatory agents for treating inflammatory bowel disease.
  • To highlight the promise of biological agents compared to other therapeutic classes.

Main Methods:

  • Literature review of immunomodulatory agents for IBD.
  • Comparative analysis of efficacy and novelty of different treatment classes.

Main Results:

  • Newer immunosuppressants (tacrolimus, mycophenolate) offer comparable alternatives but limited advancement.

Related Experiment Videos

  • Eicosanoid modulators like fish oil show modest potency.
  • Biological agents represent a novel and powerful therapeutic approach for IBD.

    • Conclusions:

    • Biological agents, including Natalizumab and targeted mucosal delivery of interleukin-10, demonstrate considerable promise for IBD treatment.
    • Further research into biologics is warranted for optimizing IBD therapy.